Liquidia (LQDA) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- $0.74
- Estimate
- $0.84
- Surprise
- -11.5%
- Revenue (period 2026-06-30)
- $171.7M
- Score at report (before → after)
- 6.1 → 5.8/10
Revenue source: xbrl.
How the report landed
Liquidia (LQDA) missed the $0.84 estimate with adjusted EPS of $0.74 — a large 11.5% shortfall. TrendMatrix's engine moved from Hold (6.1/10) to Sell at 5.8/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates LQDA Buy (Wait) at 7.0/10.
2 of the last 4 quarters beat the estimate; this quarter's -11.5% surprise compares with a +12.4% four-quarter average. Next scheduled report: 2026-11-03.
What supports the rating
- V7 flight-to-quality bonus: +0.5 (Q=8.8 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Product: YUTREPIA
- Concentration risk — Supplier: single suppliers for YUTREPIA
- Consecutive earnings misses (2)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $26.81
- Entry target
- $25.59
- Price target
- $42.92
- Stop
- $23.80
- Upside to target
- +60.1%
- Reward-to-risk
- 4.0:1
The stock trades at 19.3× trailing but 11.2× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 18 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-10-14 — shown for context, not personalized investment advice.
LQDA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $2.40B
- P/E (fwd)
- 11.2
- P/E (ttm)
- 19.3
- 52-week range
- $21.94–$93.61
- Off 52-week high
- 71.4%
- RSI (14)
- 18
- Volume vs avg
- 1.42×
- Score today
- 7.0/10